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Purpose. To study the in vitro photocytotoxicity and cellular uptake of biodegradable polymeric micelles
loaded with the photosensitizer mTHPC, including the effect of lipase-catalyzed micelle degradation.
Methods. Micelles of mPEG750-b-oligo(ɛ-caprolactone)5 (mPEG750-b-OCL5) with a hydroxyl (OH),
benzoyl (Bz) or naphthoyl (Np) end group were formed and loaded with mTHPC by the film hydration
method. The cellular uptake of the loaded micelles, and their photocytotoxicity on human neck
squamous carcinoma cells in the absence and presence of lipase were compared with free and liposomal
mTHPC (Fospeg®).
Results. Micelles composed of mPEG750-b-OCL5 with benzoyl and naphtoyl end groups had the highest
loading capacity up to 30% (w/w), likely due to π–π interactions between the aromatic end group and the
photosensitizer. MTHPC-loaded benzoylated micelles (0.5 mg/mL polymer) did not display photo-
cytotoxicity or any mTHPC-uptake by the cells, in contrast to free and liposomal mTHPC. After dilution
of the micelles below the critical aggregation concentration (CAC), or after micelle degradation by
lipase, photocytotoxicity and cellular uptake of mTHPC were restored.
Conclusion. The high loading capacity of the micelles, the high stability of mTHPC-loaded micelles
above the CAC, and the lipase-induced release of the photosensitizer makes these micelles very
promising carriers for photodynamic therapy in vivo.
KEY WORDS: drug release; enzymatic degradation; meta-tetra(hydroxyphenyl)chlorin (mTHPC);
photodynamic therapy (PDT); polymeric micelles.
INTRODUCTION
Photodynamic therapy (PDT) is an emerging method to
treat superficial tumors, for example in the head/neck region,
the digestive tract and the skin (1,2). PDT uses a combination
of a photosensitizer (PS) and laser light. Upon illumination of
the photosensitizer in the presence of oxygen, reactive
oxygen species (ROS) are formed. The anti-tumor effect of
ROS is exerted either directly by killing tumor cells, or
indirectly by damaging tumor-associated vasculature and
inducing an immune response against the tumor cells (1–3).
PDT has many advantages compared to other cancer treat-
ments, i.e. less invasive than surgery, and more targeted than
chemotherapy as a result of selective illumination.
Meta-tetra(hydroxyphenyl)chlorine (mTHPC or temo-
porfin, Fig. 1) is a second-generation PS, which is currently
clinically used as a formulation in ethanol and propylene
glycol (Foscan®). It is registered for the palliative treatment
of advanced head and neck squamous cell carcinoma
(Biolitec AG: Foscan®, summary of product characteristics),
and its clinical efficacy has been studied in PDT of other
malignancies as well, such as prostate cancer (4), oral
squamous cell carcinoma (5), and as adjuvant therapy in
combination with surgery in pleural mesothelioma (6).
Although mTHPC performs better than other first- and
second-generation PSs, like photofrin and meta-tetra(hydrox-
yphenyl)porphyrin (mTHPP) in terms of potency, depth of
PDT effect and daylight induced skin toxicity (1,3,7), further
improvement is needed with regard to its formulation and
biodistribution. Analogous to other PSs, mTHPC is highly
hydrophobic, which complicates its formulation and adminis-
tration. In patients, precipitation and adsorption of mTHPC
to the endothelium of the injected vein and adjacent
subcutaneous fat tissue have been observed after intravenous
administration of Foscan® (8), and the biodistribution of
mTHPC is influenced by its aggregation in the circulation and
complexation to serum proteins (9). In addition, skin
accumulation obligates patients to prevent exposure to light
during the first days after receiving Foscan® (10). The
therapeutic index of mTHPC may be greatly improved by
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enhancing its tumor accumulation and reducing the skin
accumulation. To optimize PDT with mTHPC, alternative,
water-soluble formulations were developed. PEG–mTHPC
conjugates were designed and their efficacy was shown to
depend on the linker used to couple PEG to the PS.
However, the therapeutic effect of these conjugates was at
best similar to native mTHPC (11–13). Encapsulation of
mTHPC in bare liposomes (Foslip®) resulted, in vitro, in
similar cellular uptake and photocytotoxic characteristics
compared to Foscan® (8). MTHPC has also been incorporat-
ed in PEGylated liposomes (Fospeg®) (14,15). A two to four
times higher bioavailability in the tumor, 5.5 times earlier
maximal tumor accumulation and four times higher tumor-to-
skin ratio compared to Foscan® was found (14), which
indicates that PEGylation of the delivery vehicle could be a
very interesting approach to formulate mTHPC for in vivo
use. However, mTHPC is still rapidly redistributed from the
Fospeg® formulation to serum components upon intravenous
injection (Biolitec AG, personal communication). Although
the amount of released mTHPC is not quantified yet, binding
of mTHPC to serum components could lead to loss in target
specificity. Furthermore, although (PEGylated) liposomes are
very promising for in vivo application, the release of the
contents from these systems can generally not be triggered by
environmental factors. Alternatively, polymeric micelles are
suitable for the formulation and targeted delivery of PSs to
tumors. Their hydrophobic core can accommodate hydropho-
bic drugs, whereas their hydrophilic shell, which is usually
composed of poly(ethylene glycol) (PEG), in combination
with their small size (10–100 nm) results in long circulation
times, allowing selective accumulation at the tumor site by the
so-called enhanced permeability and retention (EPR) effect
(16–23). To obtain the best profit of these favorable features,
a high loading capacity, i.e. drug/polymer ratio, is desired and
the drug should be stably incorporated in de micellar core
until it reaches the target site. Several PS-loaded micelles
have been studied (22), such as Pluronic or PEG2000-
distearoylphosphatidyl ethanolamine (DSPE) micelles loaded
with meso-tetraphenylporphine (mTPP) (24), aluminium
phthalocyanine loaded pH-responsive micelles (25,26), or
thermosensitive micelles loaded with solketal-substituted
phthalocyanine (27). Micelles that can be triggered by
environmental factors to release their contents are of
particular interest for selective delivery of PSs to the tumor
tissue (25,27–30). Until now there are no formulations
available that can stably entrap mTHPC and deliver it
directly to the tumor where it is released as a result of an
environmental trigger. Therefore, polymeric micelles that
degrade at their site of action are attractive systems for the
formulation and delivery of mTHPC in vivo.
In this study we evaluated the suitability of biodegrad-
able mPEG750-b-oligo(ɛ-caprolactone) based micelles for the
formulation of mTHPC. These micelles can be easily
prepared by the film-hydration method (31), and their small
size (sub-20 nm) may result in better properties in terms of
biodistribution and tumor penetration, compared to the
larger micelles studied so far (32–34). Moreover, it is
expected that stable drug incorporation can be obtained, as
a result of derivatization of the terminal hydroxyl groups of
mPEG-b-oligo(ɛ-caprolactone)s with an aromatic group,
which may improve the compatibility between the mTHPC
and the core, thereby stabilizing the drug-loaded micelles
(35–39). Therefore, the loading of mPEG-b-oligo(ɛ-caprolac-
tone) based micelles with and without end group modification
was studied, followed by examination of the photocytotoxic
effect and cellular uptake of the mTHPC loaded micelles, and
the influence of lipase, a hydrolytic enzyme, thereon.
MATERIALS AND METHODS
Materials
Acetonitrile (ACN), dichloromethane (DCM), tetrahydro-
furane (THF), and dimethylformamide (DMF) were obtained
from Biosolve Ltd. (Valkenswaard, The Netherlands). MTHPC
(meta-tetra(hydroxyphenyl)chlorine) and Fospeg® (mTHPC
encapsulated in PEGylated liposomes, 1.5 mg/mL mTHPC)
were kindly supplied by Biolitec AG (Jena, Germany).
Pseudomonas lipase (30 U/mg, 1 U produces 1 μmol glycerol
from a triglyceride per min at pH 7.0 at 37°C in the presence of
bovine serum albumin) was purchased from Sigma Aldrich
Chemie BV (Zwijndrecht, The Netherlands). Phosphate
buffered saline (PBS, pH 7.4) was obtained from Braun
Melsungen AG (Melsungen, Germany), and was filtered
through a 20 nm filter (Anotop®, Whatmann, Breda, The
Netherlands) prior to use.
Methoxylated poly(ethylene glycol)-b-oligo(ɛ-caprolac-
tone) (mPEG750-b-OCL5) block copolymers with a mono-
disperse CL-block and different end groups (Fig. 2) were
prepared as described previously (31). In brief, mPEG750-b-
OCL5 was synthesized by ring-opening polymerization of ɛ-
caprolactone (20 g, 175 mmol), initiated by mPEG750 (Mn=
750 Da, 26 g, 35 mmol) and catalyzed by SnOct2 (0.71 g,
1.8 mmol) overnight at a temperature of 130°C. To obtain
benzoylated and naphthoylated mPEG750-b-OCL5
(mPEG750-b-OCL5-Bz, mPEG750-b-OCL5-Np, respectively)
(Fig. 2b and c) the hydroxyl end groups were reacted with a
N HN
NNH
HO
OH
OH
HO
Fig. 1. Structural formula of mTHPC (meta-tetra(hydroxyphenyl)
chlorine, temoporfin).
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five fold excess of benzoyl- or 2-naphthoyl-chloride in the
presence of an equimolar amount of triethyl amine as HCl
scavenger. The polydisperse block copolymers were fraction-
ated by preparative reversed phase HPLC (RP-HPLC) to
yield monodisperse hydrophobic blocks with exactly five ɛ-
caprolactone units, as reported elsewhere (31).
The human head and neck squamous carcinoma cell line
UM-SCC-14C (further abbreviated as 14C), originally de-
scribed by Dr. T.E. Carey (Ann Arbor, MI), was kindly
provided by Prof. Dr. G.A.M.S. van Dongen (Department of
Otolaryngology/Head and Neck Surgery, VU Medical Center,
Amsterdam, The Netherlands). 14C cells were cultured at 37°C
in a 5% CO2-containing humidified atmosphere in Dulbecco’s
modified Eagle’s medium (DMEM) with 3.7 g/L sodium
bicarbonate and 4.5 g/L glucose, supplemented with 5% (v/v)
heat-inactivated fetal calf serum, 100 IU/mL penicillin, 100 μg/
mL streptomycin sulfate, and 0.25 μg/mL amphotericin B
(Gibco, Breda, The Netherlands).
Formation of mTHPC Loaded mPEG750-b-OCL5 Micelles
Micelles were formed by the film-hydration method, as
described previously (31). Typically, a block copolymer film
(10 mg) was formed by solvent evaporation from a 10 mg/mL
solution (1 mL) of the polymer in dichloromethane in a
10 mL round bottomed flask. After drying of the film for
30 min under a N2 stream, it was hydrated with 1.0 mL PBS at
room temperature. The resulting dispersion was filtered
through a 200 nm filter (Anotop®, Whatmann, Breda, The
Netherlands) (31). Similarly, mTHPC loaded micelles were
obtained at different feed ratios by addition of 0.20, 0.30, 0.40,
0.60, or 1.0 mL of a 5.0 mg/mL stock solution of mTHPC in
THF to the polymer solution, prior to evaporation of the
solvent, representing feed ratios of 10, 15, 20, 30 or 50% (w/w)
mTHPC/polymer, respectively. During all procedures the
samples were covered with aluminum foil to avoid photo-
chemical degradation of the photosensitizer.
Analysis of mTHPC Loaded mPEG750-b-OCL5 Micelles
The concentration of mTHPC in the micellar dispersions
was determined after their dilution in DMF to dissolve the
micelles. The absorbance was measured at 417 nm with a
Perkin-Elmer Lambda 2 UV–Vis spectrophotometer, using a
calibration curve of mTHPC in DMF, which was linear
between 0 and 6 μg/mL. The loading efficiency (LE) and
loading capacity (LC) were calculated by Eqs. 1 and 2,
respectively.
LE %ð Þ ¼ mass of mTHPC loaded
mass of mTHPC fed
 100% ð1Þ
LC %ð Þ ¼ mass of mTHPC loaded
mass of polymer added
 100% ð2Þ
Absorption spectra were recorded of mTHPC loaded
micelles after 20 fold dilution in PBS (final mTHPC
concentration 4 μM, polymer concentration 0.5 mg/mL) and
of free mTHPC diluted in DMF to the same concentration.
Micelles loaded with 15% (w/w) mTHPC were analyzed
by cryogenic transmission electron microscopy (Cryo-TEM).
A Tecnai12 transmission electron microscope (Philips) was
used, operating at 120 kV, with the specimen at −180°C and
low-dose imaging conditions. Samples were prepared in a
temperature and humidity-controlled chamber, using a ‘Vitro-
bot’. A thin aqueous film of micelle dispersion was formed by
blotting a 200 mesh copper grid covered with Quantifoil holey
carbon foil (Micro Tools GmbH, Germany) at 25°C and at
100% relative humidity (glow discharged grid; 1 blot during
0.5 s), followed by rapid vitrification by plunging the grid into
liquid ethane, and transfer into the microscope chamber using
a GATAN 626 cryo-holder system. Images were recorded on
a TemCam-0124 camera and processed with AnalySIS
software.
The stability of the different samples was visually
inspected at 1, 2, 4, and 8 h after preparation, and subsequently
every day. Immediately after preparation, a micellar dispersion
of mTHPC has a clear, brown-red appearance, whereas
turbidity or precipitate formation indicates the presence of
free mTHPC, which is hardly soluble in buffer.
Photocytotoxicity of mTHPC Loaded Micelles
The in vitro photocytotoxic effect of mTHPC loaded
mPEG750-b-OCL5-Bz micelles, on 14C carcinoma cells was
determined and compared to free mTHPC and liposomal
mTHPC (Fospeg®). Two series of mTHPC loaded micelles
were prepared. In the first series, a constant polymer
concentration was used (10 mg/mL) and the loading with
mTHPC was varied from 0.007% to 0.27%. These formula-
tions were 20 times diluted in culture medium, yielding a
concentration of mTHPC ranging from 0.05 to 2 μM and a
final polymer concentration of 0.5 mg/mL (which is well
above the critical aggregation concentration). The second
series were prepared by diluting a stock of 15% (w/w) loaded
micelles (1.5 mg/mL mTHPC, 10 mg/mL polymer) in culture
medium to the desired concentration range for the in vitro
PDT experiments, i.e. 0.05 to 2 μM mTHPC (final polymer
concentration 0.24 to 9 μg/mL). Fospeg® was diluted first in
PBS, followed by 20 times dilution in culture medium; free
mTHPC was diluted in THF, followed by 200 times dilution in
culture medium (final mTHPC concentrations ranging from
0.05 to 2 μM; the final THF concentration of 0.5% (v/v) has
been shown not to affect the cell viability (27)).
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Fig. 2. Structural formulas of mPEG750-b-oligo(ɛ-caprolactone)5
(mPEG750-b-OCL5-OH) (a), benzoylated mPEG750-b-OCL5 (-Bz)
(b) and naphthoylated mPEG750-b-OCL5 (-Np) (c). The average
degree of polymerization of mPEG750 is 17.
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14C cells were seeded in a 96-well plate at a density of
2×104 cells per well and cultured overnight. Then the medium
was removed and 100 μL fresh medium containing the
different mTHPC formulations was added. After incubation
of the plates for 6 h in the dark at 37°C in a 5% CO2-
containing humidified atmosphere, the medium was removed,
the cells were washed twice with 100 μL PBS, and 100 μL of
fresh medium was added.
The plates were illuminated for 10 min with 3.5 mW/cm2
light intensity, using a home made device consisting of 96
LED lamps (670±10 nm, 1 LED per well), connected to a
water bath thermostated at 37°C. An Orion Laser power/
energy monitor (Ophir Optronics LTD, Jerusalem, Israel)
was used to measure the light intensity (27). After
illumination the cells were incubated overnight in the dark
at 37°C in a 5% CO2-containing humidified atmosphere, and
the number of viable cells was determined by an XTT
colorimetric assay (40). The results are expressed as relative
cell viability, which is the percentage of viable cells relative to
non-treated cells. As a control, for every plate an identical
plate was prepared, which was not illuminated.
In a separate experiment, the effect of lipase on the
photocytotoxicity of mTHPC loaded micelles was investigat-
ed. The same procedure was followed as described above, but
before addition to the cells, a micelle-dispersion in medium,
containing 0.5 mg/mL mPEG750-b-OCL5-Bz and 0.4 μM
mTHPC was incubated with 0.3 mU/mL of lipase for 48 h at
37°C. It was previously demonstrated that at this lipase-to-
polymer ratio the micelles are fully degraded after approxi-
mately 30 h (41). As a control, the micelles were incubated
without lipase, and to test the effect of lipase on the cells,
medium without micelles was incubated with 0.3 mU/mL
lipase as well.
Cellular Uptake of mTHPC Loaded Micelles
14C cells were seeded in a 24-well plate at a density of
15×104 cells per well and cultured overnight. The medium
was removed, the cells were washed with 500 μL PBS and
500 μL fresh medium containing 10 μM of mTHPC was
added. This was either a 200-fold dilution of mTHPC-solution
in THF, or a 20-fold dilution of diluted Fospeg®, or two types
of micellar mTHPC-samples in PBS, i.e. either diluted micelles
at mTHPC/mPEG750-b-OCL5-Bz ratio of 15% (w/w), or at a
relatively high final mPEG750-b-OCL5-Bz concentration of
0.5 mg/mL in culture medium. The micelles were either
freshly prepared or incubated for 48 h at 37°C in the absence
or presence of lipase (0.3 mU/mL).
The cells were incubated with mTHPC for 6 h in the
dark at 37°C in a 5% CO2-containing humidified atmosphere.
Subsequently, the medium was removed and the cells were
washed twice with 500 μL PBS. The cells were lysed by
addition of 500 μL of lysis buffer (pH 8, 50 mM Tris/HCl,
150 mM NaCl, 1% v/w Triton X-100) followed by incubation
on ice for 20 min. The concentration of mTHPC in cell lysate
was determined by fluorescence spectroscopy, using a Horiba
Fluorolog fluorimeter at a 90° angle with a λex of 417 and λem
of 653 nm. A calibration curve was prepared in DMF with
10% (v/v) cell lysate, and was linear from 0.73 to 60 nM
mTHPC. The cellular protein concentration in a 20 μL
aliquot of the cell lysates was determined using the Micro
BCA® protein assay (42) (Pierce, Rockford, USA), following
the instructions of the supplier. The cellular uptake of
mTHPC is expressed as nanomole mTHPC per milligram
cellular protein.
RESULTS
Loading of mPEG750-b-OCL5 Based Micelles with mTHPC
mTHPC loaded micelles were prepared by hydration
with PBS of a polymer film of mPEG750-b-OCL5-OH, -Bz, or
-Np (see Fig. 2) containing different amounts of mTHPC.
Block polymers with 5 caprolactone units were used, because
these polymers are able to form sub 20-nm micelles, and have
favorable thermal characteristics (Krafft point <4°C; cloud
point >37°C) as reported previously (31).
The loading efficiency and loading capacity of the
micellar dispersions are presented in Fig. 3a and b, respec-
tively. It was shown that at mTHPC/polymer feed ratios up to
30% (w/w), the loading efficiency was almost quantitative
(80–100%), resulting in loading capacities up to 30% and an
mTHPC concentration in the dispersion of 3 mg/mL, which is
markedly higher than the aqueous solubility of mTHPC
(<100 μg/mL) (Biolitec AG: Physicochemical characteristics
of temoporfin). At 10% (w/w) loading, the dispersions stayed
clear for more than a week. At higher loading of 20% and
30% (w/w), a precipitate was observed in the dispersions of
loaded mPEG750-b-OCL5-OH micelles within 1 day after
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Fig. 3. Loading efficiency (a) and loading capacity (b) of mTHPC
into micelles composed of mPEG750-b-OCL5 with a hydroxyl,
benzoyl or naphthoyl end group. The bars represent the average ±
SD (n=3). The stability of the dispersions marked with an asterisk
was less than 1 day.
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preparation, indicating that the loading capacity of these
micelles was exceeded. In contrast, the micelle dispersions
composed of mPEG750-b-OCL5 with an aromatic end group
(Bz or Np) remained clear for more than a week at 20% and
2 days for 30% loading, which demonstrates that these end
groups have a favorable effect on the loading and solubiliza-
tion capacity of the micelles, as shown previously for the
taxanes paclitaxel and docetaxel (31,43). At a feed ratio of
50% (w/w), low loading efficiency (Bz and Np) and/or rapid
precipitation in the dispersions (OH) was obtained, which
suggests that at this point the loading capacity of all types of
micelles was exceeded.
The absorption spectrum of mTHPC formulated in
mPEG750-b-OCL5-Bz micelles in PBS (4.4 μM mTHPC,
0.5 mg/mL polymer) was very similar to that of molecularly
dissolved mTHPC (4.4 μM) in DMF (Fig. 4), i.e. no
broadening or shift of the absorption bands was observed,
indicating that mTHPC was molecularly dissolved at this
concentration in the micellar core and not incorporated as
dimers or larger aggregates (44,45).
DLS could not be used to examine the size of the loaded
micelles due to absorption of the laser light by the encapsulated
mTHPC. Therefore, cryo-TEMwas used to visualize the loaded
micelles and to determine their size. A cryo-TEM image of
mPEG750-b-OCL5-Bz micelles loaded with 15% (w/w)
mTHPC in PBS (Fig. 5) shows that they have a spherical
shape and a diameter of approximately 10 nm. This is in
agreement with the results obtained previously with empty or
taxane-loaded mPEG750-b-OCL5-Bz micelles (31,43).
Photocytotoxicity of mTHPC Loaded Micelles
The in vitro photocytotoxic effect of mTHPC loaded
mPEG750-b-OCL5-Bz micelles on 14C cells was determined
after 6 h of incubation and compared with free mTHPC and
Fospeg®. Either various dilutions of loaded micelles at a fixed
mTHPC/polymer ratio of 15% (w/w) were used, or the
polymer concentration was fixed at 0.5 mg/mL and the mTHPC
loading was varied between 0.007% and 0.27% (w/w) in order
to secure a polymer concentration of ≈100 times above its
critical aggregation concentration. Figure 6 demonstrates that
the effect on the viability of 14C cells of mTHPC-micelles at a
fixed mTHPC/polymer ratio is comparable to that of free
mTHPC and Fospeg®. The IC50 values of the diluted micellar
formulation, free mTHPC and Fospeg® were approximately
0.4, 0.2 and 0.3 μM mTHPC, respectively. Remarkably, at a
fixed high polymer concentration, the micelles with various
loadings were hardly toxic to cells even at the highest mTHPC
concentration used, i.e. 2 μM, as indicated by a cell viability
of 80%.
For the latter formulation the effect of lipase induced
degradation of the oligocaprolactone block of mPEG750-
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Fig. 4. Absorption spectra of mTHPC (4.4 μM) in DMF (solid line)
and mTHPC-loaded mPEG750-b-OCL5-Bz micelles (4.4 μM
mTHPC, 0.5 mg/mL polymer) in PBS (dashed line). The latter
spectrum was lifted by 0.05 absorbance units for clarity.
200 nm
Fig. 5. Cryo-TEM image of mPEG750-b-OCL5-Bz micelles loaded
with 15% (w/w) of mTHPC, at a polymer concentration of 10 mg/mL
in PBS. The diameter of the particles is approximately 10 nm.
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Fig. 6. Relative cell viability upon illumination of 14C cells after 6 h
of incubation in the presence of free mTHPC (empty squares),
Fospeg® (empty triangles) or mTHPC that was loaded in mPEG750-
b-OCL5-Bz micelles at a fixed mTHPC/polymer ratio of 15% (w/w)
(empty circles) or a fixed polymer concentration of 0.5 mg/mL (filled
circles). Data are presented as average ± SD (n=3). None of the
formulations displayed any dark toxicity (results not shown).
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OCL5-Bz on the photocytotoxicity was studied, at a concen-
tration of 0.4 μM mTHPC (Table I). No dark toxicity was
observed for all samples. Interestingly, when the micellar
dispersion with 0.5 mg/mL polymer was incubated with lipase
prior to adding them to the cells, an extensive decrease in cell
viability was observed, i.e. approximately 70 times compared
to the non-incubated formulation, whereas the lipase did not
affect the cell viability, nor did addition of the micelles that
were pre-incubated without lipase.
Cellular Uptake of mTHPC Loaded Micelles
Loaded micelles (with and without pre-incubation with
lipase), Fospeg® and free mTHPC were diluted in medium to
a concentration of 10 μM mTHPC and incubated with 14C
cells for 6 h to determine the cellular uptake of mTHPC
(Table II). Fospeg® and 15% (w/w) mTHPC loaded
mPEG750-b-OCL5-Bz micelles showed a lower cellular
uptake of mTHPC compared to free mTHPC, i.e. by a factor
of 3.6 and 4.8, respectively. More importantly, hardly any
mTHPC uptake was measured after incubation with the
micelles composed of 0.5 mg/mL mPEG750-b-OCL5-Bz and
10 μM mTHPC. Interestingly, incubation of the latter
formulation with 0.3 mU/mL of lipase resulted in an extensive
increase in the uptake of mTHPC by the 14C cells, yielding a
cellular uptake comparable to free mTHPC.
DISCUSSION
The loading of mTHPC in mPEG750-b-OCL5 based
micelles with three different end groups was studied. Stable
mTHPC-loaded mPEG750-b-OCL5-OH micelles were
formed with a loading capacity of 10% (w/w). This is higher
than the loading capacities of other PS-containing micelles,
such as meso-tetraphenylporphine (mTPP) in Pluronic
micelles (4%) (24), aluminium phthalocyanine in pH respon-
sive micelles (3%) (25), or solketal substituted phthalocya-
nine in thermosensitive micelles (2%) (27), and comparable
to mTPP in PEG2000-DSPE micelles (9%) (24). The
excellent loading capacity of mPEG750-b-OCL5 based
micelles may be partly explained by the preparation method
of the micelles, as it has been reported that a higher loading
of hydrophobic drugs into polymeric micelles can be obtained
with the film hydration method when compared to the
solvent-evaporation or the dialysis method (36). Interestingly,
when block polymers with an aromatic end group were used,
even higher loading capacities of up to 28% (w/w) were
obtained, indicating that the loading capacity and stability of
these micelles strongly depend on the micellar core structure.
In line herewith, it was demonstrated previously that the
presence of an aromatic end group favorably affected
the encapsulation of taxanes into these micelles (43). The
improved loading capacity can be ascribed to a higher
hydrophobicity of the OCL5-Bz and -Np core as compared
to the OCL5-OH core (43,46), but likely specific interactions
between mTHPC and the micellar core play a role as well.
The aromatic mTHPC may form π–π-interactions with the
benzoyl or naphthoyl end group, resulting in stable encapsu-
lation in the micellar core. Similarly, improved loading of the
aromatic anticancer drug camptothecin into PEG-b-poly(β
benzyl aspartate)-based micelles when the aromatic content
of the core-forming block was increased, was ascribed to this
type of interactions as well (36).
The stability of the mTHPC loaded micelles was shown
to be an important factor in the in vitro experiments. When a
stock solution of 15% (w/w) mTHPC-loaded mPEG750-b-
OCL5-Bz micelles was diluted to obtain a suitable concentra-
tion range for in vitro PDT, the photocytotoxicity was
comparable to that of free mTHPC and similarly diluted
Fospeg® (IC50 of ca 0.3 μM mTHPC in 14C cells, Fig. 6). At
these dilutions, the mPEG750-b-OCL5-Bz concentration (and
possibly also the lipid concentration in Fospeg®) is close to or
below the critical aggregation concentration (CAC) (31),
which means that the micelles are dissociated and mTHPC is
Table I. Viability of 14C Cells After 6 h of Incubation with Different Formulations Containing 0.4 μM mTHPC, Relative to Non-treated Cells
Sample
Relative cell viability (%)
Dark After illumination
Micelles, 0.5 mg/mL mPEG750-b-OCL5-Bz 103±10 87±6
Micelles, 0.5 mg/mL mPEG750-b-OCL5-Bz, pre-incubated for 48 h at 37°C (no lipase) 97±12 95±6
Micelles, 0.5 mg/mL mPEG750-b-OCL5-Bz, pre-incubated with 0.3 mU/mL lipase 102±7 1.2±0.7
0.3 mU/mL Lipase (no mTHPC-loaded micelles) 93±10 96±3
Data are presented as average ± SD (n=5–6).
Table II. Cellular Uptake of mTHPC, Added Either as Free Drug or in Different Formulations, by 14C Cells After 6 h of Incubation
Samplea Cellular uptake (nmol mTHPC/mg protein)
Free mTHPC 1.35±0.33
Fospeg® 0.37±0.11*
15% w/w mTHPC/mPEG750-b-OCL5-Bz
b 0.28±0.09*
Micelles, 0.5 mg/mL mPEG750-b-OCL5-Bz 0.04±0.02*
Micelles, 0.5 mg/mL mPEG750-b-OCL5-Bz, pre-incubated for 48 h at 37°C (no lipase) 0.06±0.02*
Micelles, 0.5 mg/mL mPEG750-b-OCL5-Bz, pre-incubated with 0.3 mU/mL lipase 1.32±0.24
a Final mTHPC concentration was 10 μM in each sample. Data are presented as average ± SD (n=6).
b Final polymer concentration was 0.045 mg/mL.
*p<0.05, mean value is significantly different from that of free mTHPC as determined with either the t test or the t test with Welch correction.
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actually present in its free form. Interestingly, when a
constant high polymer concentration (0.5 mg/mL) well above
the CAC of mPEG750-b-OCL5-Bz (i.e. 0.008 mg/mL (31))
was used with varying mTHPC-loadings, no photocytotoxicity
was observed up to 2 μM mTHPC, and hardly any cellular
uptake of mTHPC, in contrast to free mTHPC and Fospeg®
at the same mTHPC concentration (10 μM). After incubation
with lipase, which degrades the micelles (41), photocytotox-
icity was observed and mTHPC was taken up by 14C cells.
This remarkable controlled release property is in striking
contrast with the previously observed cytoxicity of paclitaxel
and docetaxel formulated in the same mPEG750-b-OCL5-Bz
micelles, which was not dependent on micellar degradation
(43).
The reduced uptake for the Fospeg® and 15% (w/w)
mTHPC-loaded mPEG750-b-OCL5-Bz micelles compared to
free mTHPC by a factor 3.6 and 4.8, respectively, (Table II)
does not directly correlate with the similar phototoxicity of
these three formulations. However, it must be emphasized
that the lipid and polymer concentration of Fospeg® and the
micellar formulation, respectively, were at more than 5 times
higher in the cellular uptake experiments than in the
phototoxicity study, due to the detection limits of the uptake
studies, and therefore more close to the CAC thereby better
retaining the mTHPC inside the particles.
The results of the photocytotoxicity and cellular uptake
of the different formulations suggest that when the concen-
tration of polymer is kept well above the CAC, mTHPC
remains stably encapsulated in the micelles even in the
presence of serum, and that the intact micelles are not taken
up by the cells, which may be ascribed to the presence of a
dense PEG-layer. Only after dilution of the mTHPC-loaded
mPEG750-b-OCL5-Bz micelles to polymer concentrations
below the CAC or after micelle degradation by lipase, the
released mTHPC can be taken up by 14C cells and exert its
cytotoxic effect upon illumination, as schematically shown in
Fig. 7. The relationship between the photocytotoxicity of
mTHPC and the integrity of the micelles is clearly different
from that observed previously for a solketal-substituted
phthalocyanine formulated in thermosensitive micelles (27).
At the concentrations used for the photocytotoxicity experi-
ments, the solketal-substituted phthalocyanine was not stably
entrapped in de micelles and the observed photodynamic
efficacy could be ascribed to diffusion of the photosensitizer
out of the micelles. It is anticipated that mPEG750-b-OCL5-
Bz micelles may act as a stable carrier system for mTHPC in
the blood circulation because of its stability in serum and
inhibited cellular uptake, allowing their selective accumula-
tion at the tumor site after intravenous administration by the
EPR effect (20,21). The enhanced lipase activity in tumors
compared to healthy tissue (47,48) may cause site-specific
micelle degradation and consequent mTHPC deposition.
CONCLUSIONS
MPEG750-b-OCL5-based micelles, particularly those
composed of polymers with a -Bz or -Np end group have
shown interesting features for the formulation of mTHPC.
Their high loading capacity and the high stability of mTHPC
loaded micelles makes them very promising carriers for PDT
with mTHPC in vivo. It is expected that accumulation at
tumor sites after intravenous administration is feasible,
followed by site-specific micelle degradation and subsequent
mTHPC release, which will be subject of future studies.
Cell membrane mTHPC-loaded micelles 
Dilution below CAC 
Enzymatic degradation 
Intact micelles No effect
Cell death
Cell death 
= mPEG750-b-OCL5-Bz = mTHPC 
Fig. 7. Schematic representation of the processes leading to the photocytotoxicity of mTHPC-loaded mPEG750-b-OCL5-Bz micelles. Intact
mTHPC-loaded micelles are not taken up by the cell, and do not cause cytotoxicity upon illumination. When the loaded micelles are diluted
below the critical aggregation concentration (CAC) or enzymatically degraded, mTHPC is released, taken up by the cell, and cytotoxicity is
caused upon illumination.
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